The utility of assessing C-peptide in patients with insulin-treated type 2 diabetes: a cross-sectional study
- PDF / 779,868 Bytes
- 7 Pages / 595.276 x 790.866 pts Page_size
- 67 Downloads / 173 Views
ORIGINAL ARTICLE
The utility of assessing C‑peptide in patients with insulin‑treated type 2 diabetes: a cross‑sectional study Tuccinardi Dario1 · Giorgino Riccardo1,2 · Pieralice Silvia1 · Watanabe Mikiko3 · Maggi Daria1 · Palermo Andrea1 · Defeudis Giuseppe1 · Fioriti Elvira1 · Pozzilli Paolo1,4 · Manfrini Silvia1 Received: 9 September 2020 / Accepted: 4 November 2020 © Springer-Verlag Italia S.r.l., part of Springer Nature 2020
Abstract Aims We aimed at evaluating residual β-cell function in insulin-treated patients with type 2 diabetes (T2D) while determining for the first time the difference in C-peptide level between patients on basal–bolus compared to those on the basal insulin scheme, considered as an early stage of insulin treatment, together with assessing its correlation with the presence of complications. Methods A total of 93 candidates with T2D were enrolled in this cross-sectional study and were categorized into two groups based on the insulin regimen: Basal–Bolus (BB) if on both basal and rapid acting insulin, and Basal (B) if on basal insulin only, without rapid acting injections. HbA1c, fasting C-peptide concentration and other metabolic parameters were recorded, as well as the patient medical history. Results The average fasting C-peptide was 1.81 ± 0.15 ng/mL, and its levels showed a significant inverse correlation with the duration of diabetes (r = -0.24, p = 0.03). Despite similar disease duration and metabolic control, BB participants displayed lower fasting C-peptide (p
Data Loading...
